JPMorgan Raises Its Price Target on Xenon Pharmaceuticals Xenon Pharmaceuticals Inc. 's recent price target hike by JPMorgan analyst Tessa Romero has sent shockwaves through the biotech sector.
Beneath the surface of this bullish forecast lies a complex web of factors influencing the stock's trajectory.
At the heart of Xenon's growth story is its lead candidate azetukalner, currently in Phase 3 trials for focal onset seizures.